688276 百克生物
已收盘 02-27 15:00:01
资讯
新帖
简况
每周股票复盘:百克生物(688276)2025年净亏2.72亿
证券之星 · 02:28
每周股票复盘:百克生物(688276)2025年净亏2.72亿
百克生物上市以来首亏 产品价格腰斩 股价跌剩零头
市场资讯 · 02-28 11:52
百克生物上市以来首亏 产品价格腰斩 股价跌剩零头
百克生物(688276)披露2025年度业绩快报,2月26日股价下跌0.6%
证券之星 · 02-26 23:09
百克生物(688276)披露2025年度业绩快报,2月26日股价下跌0.6%
百克生物(688276.SH)2025年度归母净亏损2.72亿元
智通财经 · 02-26 16:43
百克生物(688276.SH)2025年度归母净亏损2.72亿元
每周股票复盘:百克生物(688276)预计2025年净利亏损2.2亿至2.8亿元
证券之星 · 01-18
每周股票复盘:百克生物(688276)预计2025年净利亏损2.2亿至2.8亿元
百克生物(688276.SH)发预亏,预计2025年度归母净亏损2.2亿元到2.8亿元
智通财经 · 01-16
百克生物(688276.SH)发预亏,预计2025年度归母净亏损2.2亿元到2.8亿元
百克生物(688276)披露2025年年度业绩预亏公告,1月16日股价下跌0.3%
证券之星 · 01-16
百克生物(688276)披露2025年年度业绩预亏公告,1月16日股价下跌0.3%
流感疫情持续,防控系统工程再受考验
证券之星 · 2025-12-31
流感疫情持续,防控系统工程再受考验
每周股票复盘:百克生物(688276)更换持续督导保荐代表人
证券之星 · 2025-12-28
每周股票复盘:百克生物(688276)更换持续督导保荐代表人
百克生物:公司构建了以“升级换代、填补空白、创新突破”为方向的梯队式研发策略
证券日报 · 2025-12-12
百克生物:公司构建了以“升级换代、填补空白、创新突破”为方向的梯队式研发策略
生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?
投资时报 · 2025-11-24
生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?
11月21日百克生物跌5.81%,金鹰鑫瑞混合A基金重仓该股
证券之星 · 2025-11-21
11月21日百克生物跌5.81%,金鹰鑫瑞混合A基金重仓该股
每周股票复盘:百克生物(688276)成人百白破疫苗获临床试验批准
证券之星 · 2025-11-16
每周股票复盘:百克生物(688276)成人百白破疫苗获临床试验批准
百克生物(688276)披露选举第六届董事会职工代表董事,11月14日股价上涨1.93%
证券之星 · 2025-11-14
百克生物(688276)披露选举第六届董事会职工代表董事,11月14日股价上涨1.93%
百克生物(688276.SH):吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准
智通财经 · 2025-11-12
百克生物(688276.SH):吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准
每周股票复盘:百克生物(688276)前三季度净亏损1.58亿元
证券之星 · 2025-11-09
每周股票复盘:百克生物(688276)前三季度净亏损1.58亿元
股市必读:百克生物(688276)11月6日披露最新机构调研信息
证券之星 · 2025-11-07
股市必读:百克生物(688276)11月6日披露最新机构调研信息
百克生物:中信证券、投资者等多家机构于11月5日调研我司
证券之星 · 2025-11-06
百克生物:中信证券、投资者等多家机构于11月5日调研我司
每周股票复盘:百克生物(688276)Q3净利降179.31%
证券之星 · 2025-11-02
每周股票复盘:百克生物(688276)Q3净利降179.31%
百克生物(688276)2025年三季报简析:净利润同比下降164.76%,三费占比上升明显
证券之星 · 2025-11-01
百克生物(688276)2025年三季报简析:净利润同比下降164.76%,三费占比上升明显
暂无数据
公司概况
公司名称:
长春百克生物科技股份公司
所属行业:
医药制造业
上市日期:
2021-06-25
主营业务:
长春百克生物科技股份公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗等。公司被吉林省科技厅认定为高新技术企业,批准设立“吉林省疫苗科技创新中心”、被吉林省发改委批准设立“吉林省疫苗工程研究中心”、被长春国家生物产业基地认定为“长春国家生物产业基地疫苗工程研究中心”、被吉林省工信厅认定为“省级企业技术中心”。
发行价格:
36.35
{"stockData":{"symbol":"688276","market":"SH","secType":"STK","nameCN":"百克生物","latestPrice":19.63,"timestamp":1772175601000,"preClose":19.73,"halted":0,"volume":1729037,"delay":0,"changeRate":-0.0051,"floatShares":413999999,"shares":413999999,"eps":-0.4123,"marketStatus":"已收盘","change":-0.1,"latestTime":"02-27 15:00:01","open":19.68,"high":19.72,"low":19.6,"amount":33988200,"amplitude":0.0061,"askPrice":19.65,"askSize":5,"bidPrice":19.63,"bidSize":239,"shortable":0,"etf":0,"ttmEps":-0.4123,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":19.73,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":21.7,"lowLimit":17.76,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":413657598,"isCdr":false,"pbRate":2.05,"roa":"--","roe":"--","epsLYR":0.56,"committee":0.190802,"marketValue":8120000000,"turnoverRate":0.0042,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-03-02。","afterMarket":{"amount":0,"volume":0,"close":19.63,"buyVolume":0,"sellVolume":0,"time":1772177637558,"indexStatus":"已收盘 02-27 15:30:00","preClose":19.73},"floatMarketCap":8120000000},"requestUrl":"/m/hq/s/688276/tweets","defaultTab":"tweets","newsList":[{"id":"2616384306","title":"每周股票复盘:百克生物(688276)2025年净亏2.72亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616384306","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616384306?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:28","pubTimestamp":1772303293,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,百克生物报收于19.63元,较上周的19.52元上涨0.56%。本周,百克生物2月26日盘中最高价报19.99元。本周关注点来自业绩披露要点:百克生物2025年归属净利润亏损2.721亿元,同比由盈转亏。来自公司公告汇总:营业总收入同比下降51.85%,主因带状疱疹疫苗退货及水痘疫苗销量下滑。主要原因为带状疱疹疫苗收入确认后因未接种导致退货、疫苗单价下调以及水痘疫苗销量下滑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2614897821","title":"百克生物上市以来首亏 产品价格腰斩 股价跌剩零头","url":"https://stock-news.laohu8.com/highlight/detail?id=2614897821","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614897821?lang=zh_cn&edition=full","pubTime":"2026-02-28 11:52","pubTimestamp":1772250720,"startTime":"0","endTime":"0","summary":" 在2024年净利润腰斩后,疫苗巨头百克生物又曝出了上市以来首次年度亏损。公司最新发布的业绩快报显示,去年公司实现营业总收入5.92亿元,同比大降51.85%;归母净利润亏损2.72亿元,扣非净利润亏损2.89亿元,这也是公司自2021年上市以来首次年度亏损。 由于最近两年业绩不佳,百克生物股价已连跌三年,其中2024年和2025年该股分别大跌54%和24%,目前股价仅相当于历史高点的一成多,跌幅可谓惨烈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-28/doc-inhpiwhh9304474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2614025659","title":"百克生物(688276)披露2025年度业绩快报,2月26日股价下跌0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614025659","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614025659?lang=zh_cn&edition=full","pubTime":"2026-02-26 23:09","pubTimestamp":1772118553,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘,百克生物报收于19.73元,较前一交易日下跌0.6%,最新总市值为81.61亿元。该股当日开盘19.9元,最高19.99元,最低19.71元,成交额达3387.1万元,换手率为0.41%。近日,长春百克生物科技股份公司发布2025年度业绩快报。公告指出,主要原因为带状疱疹疫苗收入确认后因未接种导致退货、疫苗单价下调以及水痘疫苗销量下滑。上述数据为初步核算结果,未经审计,最终财务数据以公司正式披露的2025年年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2614501308","title":"百克生物(688276.SH)2025年度归母净亏损2.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614501308","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614501308?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:43","pubTimestamp":1772095401,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百克生物 发布2025年度业绩快报,报告期内,公司营业总收入5.92亿元,同比下降51.85%;归属于母公司所有者的净利润-2.72亿元,上年同期23,209.38万元,同比下降217.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2604925499","title":"每周股票复盘:百克生物(688276)预计2025年净利亏损2.2亿至2.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925499","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925499?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:15","pubTimestamp":1768680909,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,百克生物报收于20.14元,较上周的20.31元下跌0.84%。本周,百克生物1月13日盘中最高价报20.9元。百克生物预计2025年全年扣非后净利润亏损2.4亿元至3亿元。公司公告汇总长春百克生物科技股份公司预计2025年年度归属于母公司所有者的净利润为-22,000.00万元到-28,000.00万元,同比减少194.79%到220.64%,主要因带状疱疹疫苗销售收入下降、价格调整及水痘疫苗销量减少所致。同时,公司对存货计提减值准备,并因参股公司增资确认投资损失。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2603964706","title":"百克生物(688276.SH)发预亏,预计2025年度归母净亏损2.2亿元到2.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603964706","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603964706?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:11","pubTimestamp":1768558266,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百克生物(688276.SH)发布公告,公司预计2025年年度实现归属于母公司所有者的净利润亏损2.2亿元到2.8亿元,与上年同期相比,将出现亏损,减少4.52亿元到5.12亿元,同比减少194.79%到220.64%。报告期内,受行业竞争加剧、民众接种意愿不足、新生儿出生率下降等多重因素影响,公司经营环境面临阶段性挑战,2025年度净利润亏损。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"百克生物(688276.SH)发预亏,预计2025年度归母净亏损2.2亿元到2.8亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2603961992","title":"百克生物(688276)披露2025年年度业绩预亏公告,1月16日股价下跌0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603961992","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603961992?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:34","pubTimestamp":1768556088,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,百克生物报收于20.14元,较前一交易日下跌0.3%,最新总市值为83.31亿元。该股当日开盘20.3元,最高20.32元,最低19.98元,成交额达6109.21万元,换手率为0.73%。近日,长春百克生物科技股份公司发布2025年年度业绩预亏公告。公告显示,公司预计2025年年度归属于母公司所有者的净利润为-22,000.00万元到-28,000.00万元,同比减少194.79%到220.64%。此外,公司对存货计提了减值准备,并因参股公司增资确认了投资损失。上年同期归属于母公司所有者的净利润为23,209.38万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600028809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2595127727","title":"流感疫情持续,防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末,全国流感疫情持续处于高流行水平。产业链协同响应,构建多层次供应保障流感防控是一项系统工程,需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中,上市药企正通过全产业链布局,搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示,金振口服液四季度市场需求回暖,正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批,其在儿科领域的应用场景进一步拓宽。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000623","BK0060","000756","BK0114","688276","BK0185","BK0077","BK0096","BK0175","BK0186","002393","300937","BK0239","002603","BK0046","BK0196","002317","603882","BK0197","600566","BK0010","603858","600557","000999","BK0164","BK0188","BK0201","BK0236","BK0074","BK0086","BK0012","BK0284","BK0042","BK0146","SG9999001069.SGD","002728","BK0097","BK0250","BK0070","300244","301207","BK0183","600079","BK0187"],"gpt_icon":0},{"id":"2594242228","title":"每周股票复盘:百克生物(688276)更换持续督导保荐代表人","url":"https://stock-news.laohu8.com/highlight/detail?id=2594242228","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594242228?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:21","pubTimestamp":1766866868,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,百克生物报收于19.19元,较上周的19.31元下跌0.62%。本周,百克生物12月26日盘中最高价报19.36元。本周关注点公司公告汇总:百克生物更换持续督导保荐代表人,范新亮接替朱绍辉。公司首次公开发行股票的持续督导期已于2024年12月31日届满,但因募集资金尚未使用完毕,保荐机构将继续履行相关持续督导义务至募集资金使用完毕为止。公司董事会对朱绍辉先生的贡献表示感谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2590950764","title":"百克生物:公司构建了以“升级换代、填补空白、创新突破”为方向的梯队式研发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2590950764","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590950764?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:06","pubTimestamp":1765548360,"startTime":"0","endTime":"0","summary":"为了保障公司研发战略的稳步推进,支撑研发管线的持续迭代,百克生物建立了“生产一代、研发一代、储备一代”的稳健发展模式。构建了覆盖儿童疫苗、成人疫苗、多联多价疫苗、治疗性疫苗及单克隆抗体的多元化研发管线。2025年百克生物研发成果不断,公司重点研发陆续取得重要里程碑进展。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-12/doc-inhaqhvc7070535.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-12/doc-inhaqhvc7070535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2585540594","title":"生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?","url":"https://stock-news.laohu8.com/highlight/detail?id=2585540594","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585540594?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:21","pubTimestamp":1763972460,"startTime":"0","endTime":"0","summary":"编者按:拆解企业招股、估值、上市表现,以专业视角记录资本脉动。投资时间网携手标点财经联袂锻造“解码港股IPO”特别策划,深度探寻每一次资本浪潮背后的机遇与逻辑,敬请关注。投资时间 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251124/c672688967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","BK0057","000661","BK0075","BK0028","BK0188","BK0046","688276"],"gpt_icon":0},{"id":"2585190820","title":"11月21日百克生物跌5.81%,金鹰鑫瑞混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190820","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190820?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:45","pubTimestamp":1763711153,"startTime":"0","endTime":"0","summary":"证券之星消息,11月21日百克生物跌5.81%创60日新低,收盘报21.06元,换手率1.55%,成交量6.42万手,成交额1.38亿元。重仓百克生物的公募基金请见下表:根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为金鹰基金的金鹰鑫瑞混合A。金鹰鑫瑞混合A目前规模为0.58亿元,最新净值1.3043,较上一交易日下跌0.07%,近一年上涨3.2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2583654689","title":"每周股票复盘:百克生物(688276)成人百白破疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583654689","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583654689?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:35","pubTimestamp":1763238912,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:百克生物吸附无细胞百白破联合疫苗获临床试验批准。目前国内尚无针对青少年及成人的百白破疫苗获批。长春百克生物科技股份公司于2025年11月14日召开职工代表大会,选举佟雪莲女士为第六届董事会职工代表董事,任期至第六届董事会任期届满。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","688276","BK0239"],"gpt_icon":0},{"id":"2583507878","title":"百克生物(688276)披露选举第六届董事会职工代表董事,11月14日股价上涨1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583507878","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583507878?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:55","pubTimestamp":1763132119,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,百克生物报收于23.77元,较前一交易日上涨1.93%,最新总市值为98.33亿元。公司近日发布公告称,长春百克生物科技股份公司于2025年11月14日召开职工代表大会,选举佟雪莲女士为第六届董事会职工代表董事,任期至第六届董事会任期届满。本次选举后,兼任高管及职工代表董事人数未超过董事总数的二分之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2582283323","title":"百克生物(688276.SH):吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2582283323","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582283323?lang=zh_cn&edition=full","pubTime":"2025-11-12 15:38","pubTimestamp":1762933123,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 百克生物(688276.SH)发布公告,公司近日收到国家药品监督管理局下发的吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)的《药物临床试验批准通知书》。本次公司获批临床的吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)(以下简称“青少年及成人百白破疫苗”)是一种可以同时预防青少年及成人百日咳、白喉、破伤风的疫苗。接种对象为10周岁及以上人群,接种后可刺激机体产生免疫应答,用于预防百日咳、白喉、破伤风引起的侵袭性感染。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百克生物(688276.SH):吸附无细胞百(二组分)白破联合疫苗(成人及青少年用)临床试验申请获得批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2582861605","title":"每周股票复盘:百克生物(688276)前三季度净亏损1.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861605","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861605?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:49","pubTimestamp":1762631351,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,百克生物报收于21.79元,较上周的21.88元下跌0.41%。本周,百克生物11月4日盘中最高价报22.35元。研发投入17,789.79万元,占营收比例37.50%。带状疱疹疫苗销量同比减少,部分因前期确认收入的疫苗到期未接种而退货;同时公司开展惠民活动,以3-8折价格促销,导致单价下降、收入减少。Hib疫苗、重组带状疱疹疫苗、佐剂流感疫苗(四价)等5项临床试验申请获批,其中4项已取得批件;青少年及成人百白破疫苗已提交IND。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"gpt_icon":0},{"id":"2581015241","title":"股市必读:百克生物(688276)11月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2581015241","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581015241?lang=zh_cn&edition=full","pubTime":"2025-11-07 01:43","pubTimestamp":1762450989,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘,百克生物报收于21.85元,下跌1.22%,换手率0.55%,成交量2.26万手,成交额4963.27万元。带状疱疹减毒活疫苗报告期内,带状疱疹疫苗同比销量减少、收入下降。报告期内,公司获得1项液体剂型鼻喷流感减毒活疫苗的生产批件;2款在研疫苗启动I期临床试验;申请佐剂流感疫苗等临床批件5项,其中4项已经取得临床批件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700001069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2581050372","title":"百克生物:中信证券、投资者等多家机构于11月5日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2581050372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581050372?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:33","pubTimestamp":1762421618,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年11月6日百克生物发布公告称中信证券李文涛、投资者于2025年11月5日调研我司。2025年前三季度,公司研发投入17,789.79万元,占营业收入37.50%;上年同期研发投入为11,650.33万元,占营业收入比例为11.35%。报告期内,公司获得1项液体剂型鼻喷流感减毒活疫苗的生产批件;2款在研疫苗启动I期临床试验;申请佐剂流感疫苗等临床批件5项,其中4项已经取得临床批件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600027577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1997244956.HKD","LU1794554557.SGD","LU1255011170.USD","LU1720050803.USD","600030","BK1516","BK0188","LU1655091616.SGD","LU2148510915.USD","LU0405327494.USD","BK0239","BK0028","688276","BK1147","BK1564","LU1064130708.USD","BK0183","LU2289578879.USD","LU1328615791.USD","BK0196","LU1997245177.USD","LU1064131003.USD","BK0012","BK0276","BK1521","LU2495084118.USD","LU0405327148.USD","LU1997245094.SGD","06030"],"gpt_icon":0},{"id":"2580477816","title":"每周股票复盘:百克生物(688276)Q3净利降179.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580477816","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580477816?lang=zh_cn&edition=full","pubTime":"2025-11-02 07:03","pubTimestamp":1762038199,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,百克生物报收于21.88元,较上周的22.03元下跌0.68%。本周,百克生物10月27日盘中最高价报22.18元。业绩披露要点百克生物2025年三季报显示,前三季度主营收入4.74亿元,同比下降53.76%;归母净利润-1.58亿元,同比下降164.76%;扣非净利润-1.8亿元,同比下降173.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"gpt_icon":0},{"id":"2580173914","title":"百克生物(688276)2025年三季报简析:净利润同比下降164.76%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2580173914","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580173914?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:49","pubTimestamp":1761950991,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期百克生物发布2025年三季报。截至本报告期末,公司营业总收入4.74亿元,同比下降53.76%,归母净利润-1.58亿元,同比下降164.76%。本报告期百克生物三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达74.01%。受外部环境、市场竞争加剧以及受种者疫苗接种意愿下降等多方面因素的影响,公司带状疱疹疫苗销售、使用数量大幅减少,销售收入承压,对公司整体营业收入、净利润造成影响,收入、利润同比下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772350092492,"stockEarnings":[{"period":"1week","weight":0.0056},{"period":"1month","weight":-0.0424},{"period":"3month","weight":-0.0895},{"period":"6month","weight":-0.1787},{"period":"1year","weight":-0.1766},{"period":"ytd","weight":0.0408}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春百克生物科技股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10824人(较上一季度增加7.23%)","perCapita":"38216股","listingDate":"2021-06-25","address":"吉林省长春市朝阳区高新开发区火炬路1260号","registeredCapital":"41365万元","survey":" 长春百克生物科技股份公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗等。公司被吉林省科技厅认定为高新技术企业,批准设立“吉林省疫苗科技创新中心”、被吉林省发改委批准设立“吉林省疫苗工程研究中心”、被长春国家生物产业基地认定为“长春国家生物产业基地疫苗工程研究中心”、被吉林省工信厅认定为“省级企业技术中心”。","listedPrice":36.35},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百克生物,688276,百克生物股票,百克生物股票老虎,百克生物股票老虎国际,百克生物行情,百克生物股票行情,百克生物股价,百克生物股市,百克生物股票价格,百克生物股票交易,百克生物股票购买,百克生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}